Study of Natalizumab in Relapsed/Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to evaluate the safety profile and the anti-tumor
activity of 2 dose levels of natalizumab in participants with relapsed or refractory multiple
myeloma. Secondary objectives are to assess the pharmacokinetic (PK) profile of natalizumab
in this study population and to assess peripheral blood mononuclear cell (PBMC) saturation of
very late antigen-4 (VLA-4, an α4-integrin) and evaluate possible correlations with clinical
activity.